Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.44 |
| ▸ | ADH1A | P07327 | 4/20 | 0.44 |
| ▸ | ADH7 | P40394 | 3/20 | 0.44 |
| ▸ | ADH1C | P00326 | 3/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29034457 | 0.76 | — | — | |
| SCHEMBL733694 | 0.75 | — | — | |
| SCHEMBL8564505 | 0.74 | ADH1B (0.38) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL269241 | 0.72 | — | — | |
| SCHEMBL1153789 | 0.72 | — | — | |
| SCHEMBL6826230 | 0.71 | ADH1B (0.57) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL20041853 | 0.70 | ADH1B (0.38) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL10777746 | 0.70 | ADH1B (0.45) | ADH1BADH1AADH7ADH1CEPHX1 | |
| SCHEMBL21833552 | 0.69 | — | — | |
| SCHEMBL8308294 | 0.69 | ADH1B (0.37) | ADH1BADH1AADH7ADH1CEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0474767-B1 | DOPAMINE AGONISTS | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | claimed |
| EP-0474767-A4 | DOPAMINE AGONISTS | — | 1992-07-08 | — | — | EP | claimed |
| EP-0474767-A1 | DOPAMINE AGONISTS. | ABBOTT LAB (US) | 1992-03-18 | — | — | EP | claimed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | claimed |
| US-9079877-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079877-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2015-07-14 | — | — | US | disclosed |
| EP-2532660-B1 | Process for preparing chiral compounds | PFIZER PROD INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-20140187794-A1 | Process for Preparing Chiral Compounds | PFIZER INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187794-A1 | Process for Preparing Chiral Compounds | PFIZER INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-8642783-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642783-B2 | Process for preparing chiral compounds | PFIZER INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110118476-A1 | Process for Preparing Chiral Compounds | PFIZER INC. | 2011-05-19 | — | — | US | disclosed |
| WO-1996030393-A1 | A METHOD FOR THE SYNTHESIS OF MIXTURES OF COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0474767-B1 | DOPAMINE AGONISTS | ABBOTT LAB (US) | 1996-02-21 | — | — | EP | disclosed |
| US-5324483-A | Apparatus for multiple simultaneous synthesis | WARNER-LAMBERT COMPANY (US) | 1994-06-28 | — | — | US | disclosed |
| EP-0474767-A4 | DOPAMINE AGONISTS | — | 1992-07-08 | — | — | EP | disclosed |
| EP-0474767-A1 | DOPAMINE AGONISTS. | ABBOTT LAB (US) | 1992-03-18 | — | — | EP | disclosed |
| US-4994486-A | Neurological disorders | ABBOTT LABORATORIES (US) | 1991-02-19 | — | — | US | disclosed |
| WO-1990015056-A1 | DOPAMINE AGONISTS | ABBOTT LABORATORIES (US) | 1990-12-13 | — | — | WO | disclosed |
| US-4276047-A | POLYESTERS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1981-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187794-A1 | Process for Preparing Chiral Compounds | DERA, ALDOA, DPYD | ADH1B 116/4885ADH1A 24/4885ADH7 176/4885 |
| US-20110118476-A1 | Process for Preparing Chiral Compounds | DERA, ALDOA, DPYD | ADH1B 116/4885ADH1A 24/4885ADH7 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.